4 major market drivers for injectables
Conditions like diabetes, heart disease, and Alzheimer’s are growing rapidly in both global prevalence and economic impact. The sustained, intensive treatment these conditions require will increase demand for products optimized for patients with specific symptoms, side effects, and demographic profiles.
Demand continues to grow for specialized, targeted, and precision treatments—as well as the complex processes and the small, technically specialized batches these products often require. As more sensitive, highly customized biologics enter the global pipeline, their biopharma owners are under growing pressure to optimize costs and shorten timelines wherever possible.
Remote care management has surged during the pandemic, while patients themselves are eager to stay home as much as possible. This increases the pressure on biopharma companies to not only launch new treatments faster and more efficiently than ever, but also enhance those new products with features that make self-administered treatments as safe, effective, and convenient as possible.
There is now an accelerating shift from resource-intensive, clinic-based patient management to at-home, self-administered care. Empowering patients to manage their own care at home can lighten provider workloads, reduce demand for expensive clinical services, and make adherence more convenient for patients. Not surprisingly, many biopharma companies have begun to proactively target this valuable use case in their product development strategies.